Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $44
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Brian Skorney maintains an Outperform rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and raises the price target from $39 to $44.
August 08, 2024 | 11:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Brian Skorney maintains an Outperform rating on Mirum Pharmaceuticals and raises the price target from $39 to $44.
The raised price target and maintained Outperform rating by a reputable analyst are positive signals for investors, likely leading to a short-term increase in MIRM's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100